<?xml version="1.0" encoding="UTF-8"?><ns2:project xmlns:ns1="http://gtr.rcuk.ac.uk/gtr/api" xmlns:ns2="http://gtr.rcuk.ac.uk/gtr/api/project" xmlns:ns3="http://gtr.rcuk.ac.uk/gtr/api/fund" xmlns:ns4="http://gtr.rcuk.ac.uk/gtr/api/person" xmlns:ns5="http://gtr.rcuk.ac.uk/gtr/api/project/outcome" xmlns:ns6="http://gtr.rcuk.ac.uk/gtr/api/organisation" ns1:created="2026-06-03T15:52:43Z" ns1:href="http://gtr.ukri.org/gtr/api/projects/44AB718F-0FBE-42DD-A368-0285810D74B5" ns1:id="44AB718F-0FBE-42DD-A368-0285810D74B5"><ns1:links><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/3CDF7CDE-EA7B-43D5-99EA-BDE8D5F5CFFF" ns1:rel="LEAD_ORG"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/3CDF7CDE-EA7B-43D5-99EA-BDE8D5F5CFFF" ns1:rel="PARTICIPANT_ORG"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/362276FA-9E5A-44ED-B712-530B69176157" ns1:rel="PARTICIPANT_ORG"/><ns1:link ns1:end="2016-02-29T00:00:00Z" ns1:href="http://gtr.ukri.org/gtr/api/funds/73691052-D116-4398-A31E-3E312FD5488C" ns1:rel="FUND" ns1:start="2014-08-31T23:00:00Z"/></ns1:links><ns2:identifiers><ns2:identifier ns2:type="RCUK">131732</ns2:identifier></ns2:identifiers><ns2:title>Development of a 3D human cell-based model of liver fibrosis - a tale of two platforms</ns2:title><ns2:status>Closed</ns2:status><ns2:grantCategory>Feasibility Studies</ns2:grantCategory><ns2:leadFunder>Innovate UK</ns2:leadFunder><ns2:abstractText>Many liver diseases result in the development of fibrosis, the excessive accumulation of extracellular matrix proteins. Over time this process can lead to cirrhosis (severe scarring), liver failure and often requires liver transplantation. Currently the development of drugs to treat liver fibrosis is heavily reliant on animal studies to model the complex processes involved. Although animal models of liver fibrosis have proved invaluable in understanding the development and progression of the disease, we are yet to see an anti-fibrotic drug on the market. This project aims to create a human 3D in vitro cell-based model of liver fibrosis. If successful, this model will allow the quicker evaluation of potential new anti-fibrotic drugs. In the longer term, this will hopefully lead to the development of more effective anti-fibrotic therapies, improved treatments for patients and ultimately a reduction in the use of animals in fibrosis research and drug discovery.</ns2:abstractText></ns2:project>